deltatrials
Completed NA NCT00320970

Angiotensin II Antagonism of TGF-Beta 1

Angiotensin II Antagonism of TGF-Beta 1: A Candesartan Dose - TGF-Beta 1 Response Relationship Study

Sponsor: AstraZeneca

Conditions Diabetic Nephropathy Hypertension
Interventions Candesartan
Updated 5 times since 2017 Last updated: Aug 1, 2007 Started: Aug 31, 2002 Completion: Sep 30, 2004

This NA trial investigates Diabetic Nephropathy and Hypertension and is currently completed. AstraZeneca leads this study, which shows 5 recorded versions since 2002 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  4. Jun 2018 — Jan 2021 [monthly]

    Completed NA

  5. Jan 2017 — Jun 2018 [monthly]

    Completed NA

    First recorded

Aug 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Providence Health & Services
Data source: Providence Health & Services

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Spokane, United States